| 1 |
33859491 | CYP2C9*3/*3 Gene Expression Affects the Total and Free Concentrations of Valproic Acid in Pediatric Patients with Epilepsy. | 2021 |
5 |
| 2 |
34164480 | The association of adjusted plasma valproic acid concentration with CYP2C9 gene polymorphism in patients with epilepsy: a systematic review and meta-analysis. | 2021 May |
7 |
| 3 |
32385545 | Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis. | 2020 Aug |
6 |
| 4 |
32868386 | Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy. | 2020 Aug 31 |
5 |
| 5 |
29119932 | Relevance of CYP2C9 Function in Valproate Therapy. | 2019 |
16 |
| 6 |
28273397 | Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity. | 2017 Aug |
2 |
| 7 |
28315807 | Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy. | 2017 May |
3 |
| 8 |
28841884 | Early post-traumatic seizures are associated with valproic acid plasma concentrations and UGT1A6/CYP2C9 genetic polymorphisms in patients with severe traumatic brain injury. | 2017 Aug 25 |
1 |
| 9 |
27353638 | Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data. | 2016 Sep |
1 |
| 10 |
27485379 | Commentary on clinical significance of CYP2C9-status-guided valproic acid therapy in children. | 2016 Aug |
1 |
| 11 |
27485380 | In response: Commentary on clinical significance of CYP2C9-status-guided valproic acid therapy in children. | 2016 Aug |
1 |
| 12 |
25967074 | Clinical significance of CYP2C9-status guided valproic acid therapy in children. | 2015 Jun |
6 |
| 13 |
26543813 | Adverse events in a newborn on valproate therapy due to loss-of-function mutations in CYP2C9. | 2015 |
4 |
| 14 |
29771647 | Phenoconversion of CYP2C9 in epilepsy limits the predictive value of CYP2C9 genotype in optimizing valproate therapy. | 2015 Jun |
9 |
| 15 |
24794636 | Structural and energetic analysis to provide insight residues of CYP2C9, 2C11 and 2E1 involved in valproic acid dehydrogenation selectivity. | 2014 Jul 15 |
3 |
| 16 |
23099353 | Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy. | 2012 |
1 |
| 17 |
23120787 | [Valproic acid pharmacogenetics in an individual approach to treatment of women of childbearing age with epilepsy]. | 2011 |
2 |
| 18 |
20089352 | The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. | 2010 May |
1 |
| 19 |
20602621 | Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients. | 2010 Oct |
2 |
| 20 |
27713373 | Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy. | 2010 Aug 20 |
1 |
| 21 |
19756559 | Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling. | 2009 Dec |
2 |
| 22 |
17516991 | Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. | 2007 Jun |
4 |
| 23 |
16945988 | Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. | 2006 Dec |
2 |
| 24 |
14597963 | Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. | 2003 |
5 |
| 25 |
11736863 | In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). | 2001 Nov |
6 |